TransMedics
TMDX | NASDAQ
$92.21
+$0.83 (+0.91%)
At close: Nov 16, 2026, 4:00 PM ET
$91.55
-$0.66 (-0.72%)
After-hours:
Nov 16, 2026, 7:41 PM ET
TransMedics Company Profile
Company profile explainedCompany Profile
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Waleed H. Hassanein | Founder, President, Chief Executive Officer & Director |
| Fernando Araujo | Chief Financial Officer & Treasurer |
| Gerardo Hernandez | Chief Financial Officer & Treasurer |
| Anil Ranganath | Advisor |
| Matthew Forsyth | Senior Vice President, General Counsel & Corporate Secretary |
| Miriam C. Provost | Vice President of Global Regulatory Affairs |
| Nicholas Corcoran | Senior Vice President of Supply Chain & Operations |
| Tamer I. Khayal | Senior Vice President of International |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 4 | Filing |
| Sep 29, 2026 | 3 | Filing |
| Sep 14, 2026 | 4 | Filing |
| Sep 10, 2026 | 8-K | Current Report |
| Aug 17, 2026 | 4 | Filing |
| Aug 04, 2026 | 10-Q | Quarterly Report |
| Aug 04, 2026 | 8-K | Current Report |
| Jul 14, 2026 | 4 | Filing |
| Jul 14, 2026 | 4 | Filing |
| Jul 14, 2026 | 4 | Filing |
TransMedics
| Country | United States |
| IPO Date | May 2, 2019 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 898 |
| CEO | Waleed H. Hassanein |
Contact Details
200 Minuteman Road Andover,
Massachusetts 01810 United States
Stock Details
| Ticker Symbol | TMDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001756262 |
| CUSIP Number | 89377M109 |
| ISIN Number | US89377M1099 |
| SIC Code | 3845 |
Recent News
- 4 days ago / prnewswire.comDid TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
- 5 days ago / seekingalpha.comTransMedics: 2027 Setting Up To Be A Pivotal Year
- 6 days ago / zacks.comTransMedics (TMDX) Just Reclaimed the 200-Day Moving Average
- 6 days ago / seekingalpha.comTransMedics: Growth Is Accelerating Again And 2027 Looks Promising
- 7 days ago / fool.comTransMedics: 3 Key Takeaways for Long-Term Investors
- 8 days ago / zacks.comTransMedics (TMDX) Just Flashed Golden Cross Signal: Do You Buy?
- 8 days ago / zacks.comTransMedics (TMDX) Recently Broke Out Above the 50-Day Moving Average
- 10 days ago / marketbeat.comTransMedics Group Q3 Earnings Call Highlights
- 11 days ago / schaeffersresearch.comUnusual Options Volume Report: 3 Stocks Moving After Earnings
- 11 days ago / zacks.comTransMedics (TMDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Add to Watchlist
Select watchlists to add or remove TMDX